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Abstract
Background: Spirometry is essential to identify cases with obstructive lung diseases (OLDs) in primary 
care. However, knowledge about the long- term prognostic outcome among younger individuals is sparse.
Aim: To describe the predictive value of spirometry among individuals in the age groups 30–49 years 
and 45–64 years.
Design & setting: A population- based cohort study supplied with data from Danish national registries.
Method: Spirometry was performed in 905 adults aged 30–49 years in 1991 and in 1277 adults aged 
45–64 years in 2006. The participants were categorised into three groups: forced expiratory volume in 
1 second (FEV1)/forced vital capacity (FVC) <70, 70–75, and >75. They were followed throughout 2017 
using Danish national registries. Lung disease was defined as fulfilling at least one of the following: 
two prescriptions for respiratory medicine were redeemed within a year; one lung- related contact to 
the hospital; or lung- related death.
Results: In the 1991 cohort, 21% developed lung diseases and in the 2006 cohort 17% developed 
lung diseases throughout 2017. The probability of developing lung disease if FEV1/FVC 70–75 was 
35% (95% confidence interval [CI] = 25% to 44%) in the 1991 cohort and 23% (95% CI = 17% to 28%) 
in the 2006 cohort. The positive predicted value (PPV) was higher for both cohorts when focusing on 
smoking history and self- reported respiratory symptoms.
Conclusion: The initial spirometry has a high predictive value to identify cases of future lung diseases. 
In addition, the group with FEV1/FVC 70–75 had a high risk of developing lung diseases later in life, 
suggesting this group would be a meaningful target of special interest.
How this fits in
Few studies have evaluated different approaches to case finding of OLDs. To the authors' knowledge, 
there are no published studies investigating the value of spirometry (especially FEV1/FVC 70–75) in 
adults to predict later development of lung disease. This study demonstrates that GPs should pay 
attention to people with FEV1/FVC 70–75, as well as those with FEV1/FVC <70.
Introduction
The Danish Health Authority recommends that GPs offer spirometry testing to all individuals aged >35 
years with at least one of the following symptoms: cough, dyspnoea, wheeze or sputum production, 
Ørts LM et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101059
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or relevant exposure (current smoker and/or occupational exposure) to facilitate early detection of 
lung disease.1
Spirometry is essential in identification of chronic obstructive pulmonary disease (COPD) and 
asthma. An initial spirometry measures FEV1 and FVC. A fixed FEV1/FVC <70 is considered as an 
abnormal lung function and is the preferred diagnostic method by the Global Initiative for Obstructive 
Lung Disease (GOLD) as well as GPs.2 However, this method can potentially lead to overdiagnosing 
among3,4 older people and underdiagnosing among younger individuals.5,6
In a previous study7 it was found that adults with FEV1/FVC 70–75 have a higher risk of receiving 
respiratory medicine, have more GP contacts, and a lower income compared with those with a normal 
spirometry, defined as FEV1/FVC >75. This poor prognosis emphasises the importance of exploring 
the value of identifying the group with a FEV1/FVC 70–75.
Thus, this study aimed to describe the predictive value of spirometry among individuals in the age 
groups 30–49 years (1991 cohort) and 45–64 years (2006 cohort).
Method
Population
This Danish cohort study was based on data from the population based Ebeltoft Health Promotion 
Project (EHPP) initiated in 1991.8 In September 1991, 905 adults aged 30–49 years from the 
municipality of Ebeltoft (1991 cohort) were included. The participants were followed from 1991 
throughout 2017. During the 27 years of follow- up 88 participants from the 1991 cohort died. The 
registries used in this study were not established before 1995 and it was thus not possible to ensure 
that the population were in good respiratory health in 1991. A new round of health examinations were 
performed in Ebeltoft in 2006, where 1322 adults aged 45–64 years were included (2006 cohort). All 
the included participants underwent spirometry and filled in the questionnaire. From the 2006 cohort, 
45 participants were excluded who redeemed prescribed respiratory medicine or had a lung- related 
hospital contact within a period of 3 years before the spirometry in 2006, leaving 1277 for follow- up. 
During the 11 years of follow- up 76 participants from the 2006 cohort died. In total, 573 participated 
in both cohorts.
Informed consent to participate was obtained by every participant before entering the EHPP.8 The 
design and the main flow of participants are shown in Figure 1, and are explained in detail elsewhere.8
Exposure
The exposure of interest was the FEV1/FVC ratio. A direct- writing Vitalograph model R71 dry- wedge 
spirometer was used to measure lung function.9 The spirometer was calibrated in accordance with the 
guidelines.10 FEV1 and FVC were obtained from all participants based on at least three measurements 
differing by <5%. FEV1/FVC was categorised into three groups: <70, ≥70 to <75, or ≥75.
Outcome
The outcome of interest was lung disease, which was defined as fulfilling at least one of the following 
criteria: redeeming two prescriptions for respiratory medicine within 1 year; one lung- related contact 
to the hospital; or lung- related death.
Danish registries were linked to clinical measurements using the 10- digit civil registration number 
(CPR number) assigned to all Danish residents.11 In Denmark, most medication, including respiratory 
medicine, is only available on prescription. Data concerning redeemed prescription medication were 
available from 1 January 1995 in the Danish Register of Medical Product Statistics.12 Respiratory 
medicine was defined as a prescription redeemed within the Anatomical Therapeutic Chemical (ATC) 
code R03 (drugs for OLDs).
Information on lung- related contacts to the hospital was extracted from the Danish National 
Patient Registry.13 In Denmark, the International Classification of Diseases version eight (ICD-8) was 
used until 1 January 1994 and followed by the ICD version 10 (ICD-10). Lung- related hospital contact 
was defined as having at least one hospital contact (outpatient or inpatient) with the following ICD 
codes: ICD-8: 162–163 lung cancer, 466 (bronchitis) and 490–493 (emphysema and asthma); and ICD-
10: J20–23 (bronchitis), J40–47 (chronic lower respiratory diseases), and C34 and C78 (lung cancer).
 
 3 of 10
Research
Ørts LM et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101059
Figure 1  Flowchart of participant inclusion
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Finally, data on lung- related death were obtained from The Danish Register of Causes of Death,14 
which contains both the underlying cause of death and the condition or diagnosis that directly caused 
the death. Lung- related death was defined if either the direct cause of death or the underlying cause 
of death was coded with one of the following: J20–23 (bronchitis), J40–47 (chronic lower respiratory 
diseases), or C34 and C78 (lung cancer).
Covariates
From the questionnaires completed in 1991 and 2006, respectively, information was obtained on age, 
sex, respiratory symptoms (subdivided into: no, light, or severe symptoms) and smoking (subdivided 
into: never, former, or current smoker). Data were collected on weight, height, body mass index (BMI), 
and lung function based on results from the clinical examinations in 1991 and 2006, respectively.
Information on sociodemographic profile was obtained from Statistics Denmark and measured 
at inclusion in 1991 and 2006.15 Cohabitation status was defined as cohabiting or living alone. 
Income level was defined using the family’s disposable Organisation for Economic Co- operation and 
Development (OECD)- adjusted income level (mean and tertiles). Finally, educational level was defined 
as the highest attained education and divided into three groups based on UNESCO categories.16
Statistics
The characteristics of the baseline participants in 1991 and in 2006 were summarised using mean and 
standard deviations for continuous variables, and absolute frequency and percentage for categorical 
variables. The composite outcome was calculated for all participants and presented as event or no 
event. The predictive value of the spirometry test for participants with FEV1/FVC <70, ≥70 to <75, 
or ≥75 was calculated as the probability of a positive event during follow- up and presented with 
95% CI. Subanalyses were performed for participants with a smoking history, reporting of respiratory 
symptoms, or both. For the subanalyses, smoking history was dichotomised into yes (current/former) 
or no (never), and respiratory symptoms was dichotomised into yes (severe/light) or no.
All analyses comply with the Danish regulations on registry- based research17 and all data were fully 
anonymised. All statistical analyses were performed using the Stata (version 14) software package 
(https://www. stata. com).
Results
The overall number of participants included in the 1991 cohort and the 2006 cohort are shown in 
Table 1. In the 1991 cohort, the mean age was 40.3 years, 63.8% had a smoking history, and 20.4% 
reported respiratory symptoms within the last year before the health check. In the 2006 cohort, the 
mean age was 55.9 years, 47.5% had a smoking history, and 22.2% reported respiratory symptoms 
within the last year.
The present study showed that the predictive value was highest among individuals with FEV1/FVC 
<70 and lowest among FEV1/FVC >75. However, the probability of developing lung disease if FEV1/
FVC 70–75 was 35% (95% CI = 25% to 44%) in the 1991 cohort, and 23% (95% CI = 17% to 28%) in 
the 2006 cohort when looking at the overall group (Table 2).
In subgroups of participants with self- reported respiratory symptoms and/or a smoking history 
(Table 2), the predictive value was even higher. Among the participants with a FEV1/FVC 70–75 and 
self- reported respiratory symptoms, the predictive value was 61% (95% CI = 44% to 78%) in the 1991 
cohort and 36% (95% CI = 23% to 49%) in the 2006 cohort (Table 2). Focusing on the group with a 
smoking history and a FEV1/FVC 70–75, the predictive value was 38% (95% CI = 27% to 49%) in the 
1991 cohort and 25% (95% CI = 17% to 32%) in the 2006 cohort (Table 2). The distribution of the 
composite outcome is shown in Table 3.
Discussion
Summary
At a population level in both cohorts the FEV1/FVC ratio had a predictive value for development of 
lung disease later in life. As expected, the predictive value was highest among the group with a FEV1/
FVC <70. However, the groups with a FEV1/FVC 70–75 also had applicable results. This supports the 
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idea that a fixed cut- off of 70 among younger adults may underdiagnose OLD.5 By adding information 
about smoking history and self- reported respiratory symptoms as recommended,1 the PPV increased.
Strengths and limitations
A major strength of this study is the high participation rate (69% in 1991 and 57% in 2006) in a 
real- life setting with a clinical examination, including spirometry performed both in 1991 and 2006.8 
Additionally, the authors had the unique opportunity to make a complete and long- term registry- 
based follow- up from 1991 throughout 2017.
Table 1  Baseline characteristics of the 1991 cohort and the 2006 cohort
1991 cohort Missing 2006 cohort Missing
Characteristics Total n / N Total n / N
n (%) 905 (100.0) 0/905 1277 (100.0) 0/1277
Sex, male, n (%) 430 (47.5) 0/905 634 (49.6) 0/1277
Age, mean (SD) 40.3 (5.7) 0/905 55.9 (5.7) 0/1277
Living alone, n (%)
  Yes 175 (19.5) 260 (20.4)
  No 724 (80.5) 6/905 1017 (79.6) 0/1277
Education, n (%)
  Low (≤10 years) 249 (28.2) 322 (25.5)
  Medium (>10 to ≤15 years) 435 (49.3) 613 (48.6)
  High (>15 years) 199 (22.5) 22/905 327 (25.9) 15/1277
Income, 1000 euro, mean (SD) 15.2 (5.0) 8/905 33.0 (25.2) 4/1277
Income, 1000 euro, n (%)
  Low tertile 316 (34.9) 423 (33.2)
  Middle tertile 310 (34.3) 425 (33.4)
  High tertile 279 (30.8) 0/905 425 (33.4) 4/1277
Respiratory symptoms, previous year, n (%)
  No symptoms 721 (79.7) 944 (77.8)
  Light symptoms 150 (16.6) 202 (16.7)
  Severe symptoms 34 (3.8) 0/905 67 (5.5) 64/1277
Smoking status at baseline, n (%)
  Never smoker 326 (36.2) 659 (52.5)
  Current smoker 461 (51.2) 392 (31.2)
  Former smoker 113 (12.6) 5/905 204 (16.3) 22/1277
BMI, mean (SD) 25.1 (4.3) 0/905 27.1 (4.6) 0/1277
FEV1/FVC, mean (SD) 80.1 (6.2) 0/905 77.7 (7.3) 0/1277
FEV1% of predicted value, mean (SD)a 98.2 (12.2) 0/905 93.7 (15.5) 0/1277
FEV1/FVC, n (%)
  <70 52 (5.7) 138 (10.8)
  ≥70 to <75 95 (10.5) 204 (16.0)
  ≥75 758 (83.8) 0/905 935 (73.2) 0/1277
BMI = body mass index. FEV1/FVC = forced expiratory volume in 1 second/forced vital capacity. SD = standard 
deviation. aThe predicted value of FEV1 was calculated by taking the age, height, and reference values into 
account.
Ørts LM et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101059
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Table 2 Positive predictive value of a positive test calculated on the 1991 cohort and 2006 cohort
Table 2A 1991 cohort, all 2006 cohort, all
Composite outcome 1991–2017, n (95% CI) Composite outcome 2006–2017, n (95% CI)
Event No event Total Event No event Total
FEV1/FVC <70 27 25 52 56 82 138
FEV1/FVC 70–75 33 62 95 46 158 204
FEV1/FVC >75 131 627 758 115 820 935
Total 191 714 905 217 1060 1277
PPV <70 0.52 (0.38 to 0.66) 0.41 (0.32 to 0.49)
PPV 70–75 0.35 (0.25 to 0.44) 0.23 (0.17 to 0.28)
PPV >75 0.17 (0.15 to 0.20) 0.12 (0.10 to 0.14)
Table 2B 1991 cohort, respiratory symptoms 2006 cohort, respiratory symptoms
Composite outcome 1991–2017, n (95% CI) Composite outcome 2006 –2017, n (95% CI)
Event No event Total Event No event Total
FEV1/FVC <70 14 9 23 30 14 44
FEV1/FVC 70–75 19 12 31 18 32 50
FEV1/FVC >75 37 93 130 42 133 175
Total 70 114 184 90 179 269
PPV <70 0.61 (0.41 to 0.81) 0.68 (0.54 to 0.82)
PPV 70–75 0.61 (0.44 to 0.78) 0.36 (0.23 to 0.49)
PPV >75 0.28 (0.21 to 0.36) 0.24 (0.18 to 0.30)
Table 2C 1991 cohort, smoking history 2006 cohort, smoking history
Composite outcome 1991–2017, n (95% CI) Composite outcome 2006 –2017, n (95% CI)
Event No event Total Event No event Total
FEV1/FVC <70 23 21 44 37 49 86
FEV1/FVC 70–75 27 44 71 29 89 118
FEV1/FVC >75 88 371 459 61 331 392
Total 138 436 574 127 469 596
PPV <70 0.52 (0.38 to 0.67) 0.43 (0.34 to 0.52)
PPV 70–75 0.38 (0.27 to 0.49) 0.25 (0.17 to 0.32)
PPV >75 0.19 (0.16 to 0.23) 0.16 (0.12 to 0.19)
Table 2D 1991 cohort, smoking history and respiratory symptoms 2006 cohort, smoking history and respiratory symptoms
Composite outcome 1991–2017, n (95% CI) Composite outcome 2006 –2017, n (95% CI)
Event No event Total Event No event Total
FEV1/FVC <70 12 8 20 24 9 33
FEV1/FVC 70–75 15 11 26 12 21 33
FEV1/FVC >75 31 60 91 24 61 85
Total 58 79 137 60 91 151
PPV <70 0.60 (0.39 to 0.81) 0.73 (0.58 to 0.88)
PPV 70–75 0.58 (0.39 to 0.77) 0.36 (0.20 to 0.53)
PPV >75 0.34 (0.24 to 0.44) 0.28 (0.19 to 0.38)
FEV1/FVC = forced expiratory volume in 1 second/forced vital capacity. PPV = positive predictive value.
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However, there are some limitations. First, there is a risk of selection bias. It is known from previous 
studies that on average non- attendees are less healthy and have a worse socioeconomic profile than 
attendees.18,19 Furthermore, 573 participants in 2006 had a previous health check, which potentially 
could have led to more health- related talks on health promotion and smoking cessation. This has 
probably resulted in an underestimation of the predictive value in the 2006 cohort, as participants had 
followed the advice and stopped smoking between the two clinical examinations in 1991 and 2006. 
Second, the composite outcome is based on information from Danish registries. Although highly 
validated, it is possible that not all individuals with a lung disease were identified. The authors do 
not have information on diagnostic spirometry examinations performed by GPs during follow- up; 
therefore, it is possible that some patients could have had a FEV1/FVC <70 and were recommended 
to quit smoking, but not prescribed any medical treatment. If this is the event, the predictive value has 
been underestimated. To increase the specificity of the composite outcome, the study only included 
at least two prescriptions redeemed for respiratory medicine within a year as an outcome, thereby 
excluding coincidental treatment prescribed for cough or flu. Finally, the spirometry measure used 
in this study is only pre- bronchodilator measurements, which may overestimate the prevalence of 
airflow limitation.20 Yet, in the present study, the risk of overestimating was substantially reduced by 
excluding the 45 individuals with known lung diseases 3 years prior to the clinical examination in 2006. 
Unfortunately, the opportunity to exclude individuals with lung diseases 3 years prior to the clinical 
examination in 1991 did not arise, which may have overestimated the PPVs in 1991.
The invited participants were from the general population in Ebeltoft Municipality, Denmark. 
Hence, the generalisability of the findings will not only mirror certain individuals at risk; for example, 
patients with lung symptoms or current smokers. The real- life setting provided high external validity, 
as the individuals are representative for subjects to be screened for OLD in primary care. Finally, 
life expectancy has increased during the follow- up period. Smoking rates have decreased and new 
inhalers have been developed and widely introduced, which may have affected the generalisability 
of the study.21 Smoking cessation and relevant medical treatment are the primary interventions to 
improve lung function and reduce the complication rate, which may help explain the difference 
between the baseline smoking prevalence in the two cohorts22 (Table 1).
Comparison with existing literature
A variety of approaches to identify and diagnose individuals with OLD in primary care settings has been 
investigated.23–30 Guirguis- Blake et al27 compared questionnaires and spirometry as a COPD screening 
instrument. They found a higher predictive value of the spirometry (PPV 63%–75%) compared with 
the COPD diagnostic questionnaire (PPV 17%–45%). The results from the present study support the 
findings by Guirguis- Blake et al, but the highest PPV was found when combining the spirometry result 
and self- reported respiratory symptoms.
Another screening instrument is the handheld spirometer, which has been tested in different 
settings such as pharmacies, market places, and general practice.28–31 Frith et al validated the handheld 
spirometry in a high- risk population and found a PPV of 73% with a fixed ratio cut- off of 70, and a 
PPV of 52% with a fixed ratio cut- off of 75.29 Thorn et al provided an initial handheld spirometry to all 
smokers when they visited the GP for other reasons and found that 25.2% had undiagnosed COPD.28 
The study group also tested different cut- offs for fixed ratios when providing initial spirometry to a 
primary care population consisting of current smokers aged 45–85 years. The choice of use for the 
optimal fixed ratio cut- off was a FEV1/FVC < 73 where sensitivity was 79.2 and specificity was 80.3.28
Finally, the lower limit of normal (LLN) has been discussed as an alternative to the fixed ratio. 
However, clinicians favour the fixed ratio owing to simplicity and the GOLD recommendations,2 
Table 3 Description of the composite outcome in the 1991 cohort (1991–2017) and the 2006 cohort 
(2006–2017)
1991 cohort, n (%) 2006 cohort, n (%)
Positive composite outcome 191 (100) 217 (100)
Respiratory medicine 164 (85.9) 181 (83.4)
Lung- related contact to hospital 87 (45.5) 97 (44.7)
Lung- related death 16 (8.4) 18 (8.3)
Ørts LM et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101059
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whereas the demand for accuracy is used among some pulmonary physiologists and researchers 
arguing for the LLN.4,25,27
The distribution of the FEV1/FVC values among adults and middle- aged people can be explained 
by the natural history of lung function.32,33 It is expected that the FEV1/FVC will reach a 'plateau 
phase' in the mid- 20s followed by an incipient decline.32,33 On the contrary, Lange et al found that 
only one- fourth of 40 year olds with obstructive spirometry end up with COPD, which questions the 
physiological development of lung diseases.34
Implications for research and practice
In the Danish healthcare system, primary care is free of charge and 98% of Danish citizens are assigned 
to a GP.35 The GPs conduct the case finding of OLD, perform the major part of the care, including 
medicine adjustments, and motivate smoking cessation. Therefore, primary care has a huge impact 
on the state of health of patients with OLD, since it is only the most severe cases that are referred 
to a pulmonary specialist. In the present study, most of the patients with a positive event were not 
hospitalised, indicating that their disease has been managed by their GP.
Further work is needed to improve the early case finding of lung diseases in primary care. First, 
the detection of those actually at risk should be enhanced. The individuals at risk are less prone to 
participate in health promotion,18,19 recommending that the GPs should have more focus on targeted 
case finding when patients visit the GP for other reasons. Although sensitivity and specificity of the 
handheld spirometry could be improved, there are several advantages to the simple and reliable 
tool. A handheld spirometry compared with the diagnostic spirometry is time- saving; 4 minutes 17 
seconds versus 32 minutes 31 seconds, respectively. Thereby, the related costs amount to 2.12 EUR 
versus 16.07 EUR, respectively.28 The number needed to screen to detect one case of COPD is 4.6 and 
spirometry is cost- effective in the early identification of COPD.26 Still, there is a lack of spirometry use 
in general practice.36 The groups with a FEV1/FVC <70 had a PPV of 41% and 52%, which emphasises 
that less than half of patients with OLDs end up receiving medical treatment.
In conclusion, this descriptive study has shown a high risk of developing lung diseases later in life 
among those with FEV1/FVC 70–75. The findings support that early case finding of lung diseases is 
possible and suggests that both adults and middle- aged people with FEV1/FVC 70–75 should be a 
meaningful target of intervention as those with FEV1/FVC <70.
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